对精神分裂症患者行阿立哌唑替换氯丙嗪治疗的临床疗效分析

郝志君

[關键词] 精神分裂症;阿立哌唑;氯丙嗪;阴性症状;社会功能;精神病药物

[中图分类号] R749.3          [文献标识码] A          [文章编号] 1673-9701（2021）29-0024-04

Analysis of the clinical efficacy of aripiprazole in place of chlorpromazine in patients with schizophrenia

HAO Zhijun

Department of Psychiatry， Jiamusi Psychiatric Welfare Home in Heilongjiang Province， Jiamusi   154007， China

[Abstract] Objective To explore the clinical effect of aripiprazole in place of chlorpromazine in patients with schizophrenia （mainly negative symptoms）. Methods A total of 108 patients with schizophrenia who met the research conditions in our hospital from June 2017 to July 2019 were selected. The above patients were divided into two groups according to the random number table method. The observation group （n=54） was treated with aripiprazole. The control group （n=54） was treated with chlorpromazine. Clinical efficacy， negative symptom score before and after treatment， overall impression score， social function score after treatment and incidence of adverse reactions were compared between two groups. Results The total effective rate of clinical treatment in the observation group was higher than that of the control group， and the total incidence of adverse reactions in the observation group was lower than that of the control group. The difference was statistically significant（P<0.05）. At four weeks， eight weeks， and 12 weeks of treatment， the scores of the negative symptom scale （SANS） of the observation group were significantly lower than those of the control group. The scores of the clinical general impression（CGI-SI） scale in the observation group were significantly lower than those of the control group， and the differences were statistically significant （P<0.05）. After treatment， the scores of scale of social-skills for psychiatric inpatients （SSPI） （proactive， daily living ability， social activity skills） of the observation group were significantly higher than those of the control group， and the differences were statistically significant （P<0.05）. Conclusion Compared with traditional psychiatric drugs， the use of aripiprazole in the treatment of schizophrenia with negative symptoms has a significant clinical effect， which can increase the total clinical effective rate， improve negative symptoms， reduce the overall clinical impression， and improve the social function of patients. It has few adverse reactions and high safety of the clinical medication， and can be widely promoted in clinical practice.

[Key words] Schizophrenia; Aripiprazole; Chlorpromazine; Negative symptoms; Social function; Psychiatric drugs

精神分裂症属于较严重的精神病，患者表现为行为异常，情感、思维发生改变，严重影响患者正常生活质量。若采取临床相关治疗，则可缓解患者病情。但此病复发率高，病情周期性较长。结合相关数据，对以往临床治疗经验进行总结，采用传统抗精神病药物，如氟哌啶醇、氯丙嗪等，对其临床治疗效果进行观察发现，传统药物治疗精神分裂症患者疗效不明显，且药物副作用会给患者机体带来较高影响，不宜长期用药[1]。阿立哌唑属于抗精神病类主要药物，治疗精神分裂症效果良好，对控制患者病情进展具有重要帮助。本研究旨在分析阿立哌唑治疗精神分裂症的临床效果，选取108例此类患者进行说明，现报道如下。

1 资料与方法

1.1 一般资料

在2017年6月至2019年7月我院收治的所有精神分裂症患者中抽取满足研究条件的108例患者，纳入病例均符合用药规范。按照随机数字表法分为两组，观察组54例患者，男女比例为29∶25，年龄20～66岁，平均（51.65±6.74）岁，病程1～15年，平均（6.92±0.83）年;其余54例患者纳入对照组，男女比例为30∶24，年龄20～67岁，平均（51.87±6.57）岁，病程1～16年，平均（6.11±0.94）年;两组患者均无药敏史，且依从性良好。两组性别、年龄、病程比较，差异无统计学意义（P>0.05），具有可比性。本研究经医院医学伦理委员会批准。纳入标准[2]：①所选患者病历资料完善，且经患者家属知情同意;②符合用药标准者;③实验室检查无严重异常指标者;④能够正常交流沟通者。……